Standard Contracts
ROYALTY PURCHASE AGREEMENT BY AND BETWEEN APR APPLIED PHARMA RESEARCH S.A. AND SWK FUNDING LLC DATED AS OF DECEMBER 2, 2015Royalty Purchase Agreement • July 11th, 2022 • Relief Therapeutics Holding SA • Pharmaceutical preparations • New York
Contract Type FiledJuly 11th, 2022 Company Industry JurisdictionTHIS ROYALTY PURCHASE AGREEMENT entered and made effective as of this 2nd day of December, 2015 (this “Agreement”), by and between APR APPLIED PHARMA RESEARCH S.A., a corporation organized and existing according to the laws of Switzerland (“Seller”), and SWK FUNDING LLC, a Delaware limited liability company (“Purchaser”).
Royalty Purchase AgreementRoyalty Purchase Agreement • August 25th, 2006 • International Royalty Corp • British Columbia
Contract Type FiledAugust 25th, 2006 Company JurisdictionEach of the Vendors wishes to sell, and the Purchaser wishes to purchase, the Royalties on the terms and conditions set forth in this Agreement; and
ROYALTY PURCHASE AGREEMENT dated as of January 6, 2018 between ANTIGENICS LLC, as Seller and HEALTHCARE ROYALTY PARTNERS III, L.P., AND CERTAIN AFFILIATED FUNDS IDENTIFIED HEREIN, collectively as PurchaserRoyalty Purchase Agreement • July 29th, 2021 • Healthcare Royalty, Inc. • Pharmaceutical preparations • New York
Contract Type FiledJuly 29th, 2021 Company Industry JurisdictionROYALTY PURCHASE AGREEMENT (as amended, supplemented or otherwise modified from time to time, this “Agreement”) is made and entered into as of January 6, 2018, by and between ANTIGENICS LLC, a Delaware limited liability company (the “Seller”) and the entities set forth on Schedule 1 in the proportions set forth thereon (collectively, the “Purchaser”).
CERTAIN CONFIDENTIAL INFORMATION, MARKED BY [***] HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. ROYALTY PURCHASE AGREEMENT ESPERION THERAPEUTICS, INC. as...Royalty Purchase Agreement • August 12th, 2024 • Esperion Therapeutics, Inc. • Pharmaceutical preparations • New York
Contract Type FiledAugust 12th, 2024 Company Industry JurisdictionAND WHEREAS Seller desires to sell, transfer, assign and convey to Purchaser, and Purchaser desires to purchase, acquire and accept from Seller, Seller’s right, title and interest in and to the Purchased Receivables, upon and subject to the terms and conditions set forth in this Agreement;
ROYALTY PURCHASE AGREEMENT BETWEEN Dorato Resources Inc. - and - Franco-Nevada Corporation June 22, 2012 - i - - ii -Royalty Purchase Agreement • May 5th, 2020 • Ontario
Contract Type FiledMay 5th, 2020 JurisdictionTHIS ROYALTY PURCHASE AGREEMENT is dated as of the 22nd day of June, 2012, by and between Dorato Resources Inc., a corporation organized under the laws of British Columbia, whose address for purposes hereof is Suite 2300 – 1177 West Hastings Street, Vancouver, British Columbia V6E 2K3 (“Dorato”) and Franco-Nevada Corporation, a corporation organized under the laws of Canada, whose address for purposes hereof is Exchange Tower, 130 King Street West, Suite 740, PO Box 467, Toronto, Ontario M5X 1E4 (“Franco”).
Royalty Purchase Agreement By and Between PureTech Health LLC, as the Seller, and Solely for purposes of Article 4 and Section 10.13, PureTech Health PLC, as the Seller Parent, on the one hand and Royalty Pharma Investments 2019 ICAV, as the Buyer, on...Royalty Purchase Agreement • April 25th, 2024 • PureTech Health PLC • Pharmaceutical preparations • New York
Contract Type FiledApril 25th, 2024 Company Industry Jurisdiction
EX-99.75 84 exh75staticroyaltypurchasea.htm ROYALTY PURCHASE AGREEMENT Agreement made as of March 18, 2005 BetweenRoyalty Purchase Agreement • May 5th, 2020 • British Columbia
Contract Type FiledMay 5th, 2020 JurisdictionBHP Billiton World Exploration Inc., BHP Billiton Diamonds Inc., BHP Billiton Minerals Pty Ltd., BHP Minerals International Exploration Inc., BHP Minerals Ghana Inc., BHP Holdings (International) Inc., BHP Brasil Ltda., Minera BHP Billiton, S.A. De C.V. and BHP Minerals Holdings Proprietary Limited
EX-10.44 2 d307977dex1044.htm EX-10.44 CONFIDENTIAL EXECUTION VERSION [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant...Royalty Purchase Agreement • May 5th, 2020 • New York
Contract Type FiledMay 5th, 2020 JurisdictionThis ROYALTY PURCHASE AGREEMENT, dated as of February 1, 2017 (this “Agreement”), is made and entered into by and between Cytokinetics, Incorporated, a Delaware corporation (the “Seller”), on the one hand, and RPI Finance Trust, a Delaware statutory trust (the “Buyer”), on the other hand.
ROYALTY PURCHASE AGREEMENT BETWEEN NEUROSCIENCE PARTNERS LIMITED PARTNERSHIP BY ITS GENERAL PARTNER, MDS ASSOCIES-NEUROSCIENCE INC. - AND - APOLLO GENETICS, INC. DECEMBER 18, 1996Royalty Purchase Agreement • March 17th, 1997 • Apollo Biopharmaceutics Inc • Pharmaceutical preparations • Massachusetts
Contract Type FiledMarch 17th, 1997 Company Industry Jurisdiction
EX-10.2 3 a15-6181_1ex10d2.htm EX-10.2 CONFIDENTIAL TREATMENT REQUESTED ROYALTY PURCHASE AGREEMENT dated as of March 24, 2015 between IMMUNOGEN, INC., HURRICANE, LLC as Seller and IMMUNITY ROYALTY HOLDINGS, L.P.Royalty Purchase Agreement • May 5th, 2020 • New York
Contract Type FiledMay 5th, 2020 JurisdictionPortions of the exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
ContractRoyalty Purchase Agreement • November 7th, 2018 • Agenus Inc • Biological products, (no disgnostic substances) • New York
Contract Type FiledNovember 7th, 2018 Company Industry Jurisdiction[********] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. AMENDED AND RESTATED...Royalty Purchase Agreement • February 29th, 2024 • PTC Therapeutics, Inc. • Pharmaceutical preparations • New York
Contract Type FiledFebruary 29th, 2024 Company Industry JurisdictionThis AMENDED AND RESTATED ROYALTY PURCHASE AGREEMENT, dated as of October 18, 2023 (this “Agreement”), is made and entered into by and among PTC Therapeutics, Inc., a Delaware corporation (the “Seller”), Royalty Pharma Investments 2019 ICAV, an Irish collective asset-management vehicle (the “Buyer”), and, solely for the purposes of Section 5.15 hereof, Royalty Pharma plc, a limited company organized under the laws of England and Wales.
Execution Version Dated Royalty Purchase Agreement relating to Houndé Project between ACACIA MINING PLC and SANDSTORM GOLD LTD. Contents Clause Schedule Schedule 1 The Project Royalty Agreement 15 Schedule 2 The Warranties 16 THIS AGREEMENT is dated...Royalty Purchase Agreement • May 5th, 2020 • England and Wales
Contract Type FiledMay 5th, 2020 Jurisdiction
EX-10.1 2 d257386dex101.htm ROYALTY PURCHASE AGREEMENT ROYALTY PURCHASE AGREEMENTRoyalty Purchase Agreement • May 5th, 2020 • New York
Contract Type FiledMay 5th, 2020 JurisdictionThis ROYALTY PURCHASE AGREEMENT (this “Agreement”), dated November 14, 2011, is made by and between Deerfield Private Design Fund II, L.P., a Delaware limited partnership (“Design Fund II”), Deerfield Special Situations Fund, L.P., a Delaware limited partnership (“DSS”), Horizon Santé TTNP SARL, a Luxembourg limited company (“Horizon” and together with Design Fund II and DSS, “Deerfield”) and Titan Pharmaceuticals, Inc., a Delaware corporation (“Titan”).
ROYALTY PURCHASE AGREEMENT dated as of March 22, 2021 between VIRACTA THERAPEUTICS, INC., as Seller, and XOMA (US) LLC, as PurchaserRoyalty Purchase Agreement • May 13th, 2021 • Viracta Therapeutics, Inc. • Pharmaceutical preparations • Delaware
Contract Type FiledMay 13th, 2021 Company Industry JurisdictionThis ROYALTY PURCHASE AGREEMENT (this “Agreement”) dated as of March 22, 2021 (the “Effective Date”), is between VIRACTA THERAPEUTICS, INC., a corporation organized and existing under the laws of Delaware, with an office located at 2533 South Coast Highway 101, #210, Cardiff CA 92007 (“Seller”), and XOMA (US) LLC, a Delaware limited liability company with its principal place of business at 2200 Powell Street, Suite 310, Emeryville, California 94608 (“Purchaser”).
EXECUTION COPY CLAUDE RESOURCES INC. - and - 8248567 canada limited ROYALTY PURCHASE AGREEMENT March 20, 2014 Fasken Martineau DuMoulin LLP Barristers and Solicitors Global Mining Group Page Schedule “A” REPRESENTATIONS AND WARRANTIES OF CLAUDE...Royalty Purchase Agreement • May 5th, 2020 • Saskatchewan
Contract Type FiledMay 5th, 2020 JurisdictionWHEREAS, Claude Resources is the registered holder of a 100% undivided interest in and to the Property (as hereinafter defined);
Royalty Purchase AgreementRoyalty Purchase Agreement • February 19th, 2021 • Longboard Pharmaceuticals, Inc. • Pharmaceutical preparations • California
Contract Type FiledFebruary 19th, 2021 Company Industry JurisdictionThis Royalty Purchase Agreement (the “Agreement”), dated as of October 27, 2020, is by and between Arena Pharmaceuticals, Inc. (“Parent”), 356 Royalty Inc., a Delaware corporation and wholly-owned subsidiary of Parent (“356”), and Longboard Pharmaceuticals, Inc., a Delaware corporation and wholly-owned subsidiary of Parent (the “Company”). Capitalized terms used but not defined herein shall have the meaning ascribed to such terms in that certain Transaction Agreement, dated as of December 28, 2016, by and among 356, Eisai Inc. and Eisai Co., Ltd. (the “Transaction Agreement”).
ROYALTY PURCHASE AGREEMENTRoyalty Purchase Agreement • May 26th, 2015 • Medical Imaging Corp. • Services-medical laboratories
Contract Type FiledMay 26th, 2015 Company IndustryWHEREAS the Purchaser wishes to acquire from the Corporation, and the Corporation wishes to sell to the Purchaser, a gross sales royalty on the terms and conditions contained herein.
CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) OF THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. [***] INDICATES THAT INFORMATION HAS BEEN OMITTED. ROYALTY PURCHASE AGREEMENT...Royalty Purchase Agreement • August 7th, 2024 • Aclaris Therapeutics, Inc. • Pharmaceutical preparations • New York
Contract Type FiledAugust 7th, 2024 Company Industry JurisdictionAND WHEREAS Seller desires to sell, transfer, assign and convey to Purchaser, and Purchaser desires to purchase, acquire and accept from Seller, Seller’s right, title and interest in and to the Purchased Receivables, upon and subject to the terms and conditions set forth in this Agreement;
CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL ANDRoyalty Purchase Agreement • March 3rd, 2022 • Concert Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
Contract Type FiledMarch 3rd, 2022 Company Industry JurisdictionThis Royalty Purchase Agreement is dated as of November 3, 2021 (this “Agreement”), by and among Concert Pharmaceuticals, Inc., a Delaware corporation (the “Seller”), each buyer identified on the signature pages hereto (each, including its successors and assigns, a “Buyer” and collectively the “Buyers” and including the RA Buyer Representative in its capacity as such) and the BVF Buyer Representative (as defined below).
ROYALTY PURCHASE AGREEMENT dated as of December 17, 2020 between EYEPOINT PHARMACEUTICALS, INC. EYEPOINT PHARMACEUTICALS US, INC. and SWK FUNDING LLCRoyalty Purchase Agreement • March 12th, 2021 • EyePoint Pharmaceuticals, Inc. • Laboratory analytical instruments • New York
Contract Type FiledMarch 12th, 2021 Company Industry Jurisdiction
VISCHER WITH KUROS BIOSCIENCES ON ROYALTY PURCHASE AGREEMENT WITH XOMARoyalty Purchase Agreement • October 18th, 2022
Contract Type FiledOctober 18th, 2022Kuros Biosciences, a bone graft technologies company, has entered into a royalty purchase agreement with Xoma Corporation, under which Xoma has purchased a proportion of the potential future pre-commercial milestone payments and all the potential royalties due under the existing license agreement between Kuros and Checkmate Pharmaceuticals related to one of Kuros’s assets outside of the bone graft field.
ContractRoyalty Purchase Agreement • May 2nd, 2023 • Atlas Lithium Corp • Mining & quarrying of nonmetallic minerals (no fuels) • Ontario
Contract Type FiledMay 2nd, 2023 Company Industry JurisdictionCertain identified information has been excluded from the exhibit because it both (i) is not material and (ii) is the type that the company treats as private or confidential, and such information has been marked at the appropriate place with [***].
AGREEMENT TO PURCHASE ROYALTYRoyalty Purchase Agreement • March 31st, 2009 • Nord Resources Corp • Mining & quarrying of nonmetallic minerals (no fuels) • Arizona
Contract Type FiledMarch 31st, 2009 Company Industry JurisdictionThis AGREEMENT TO PURCHASE ROYALTY (“Agreement”) is made and entered into as of the 31st day of March, 2009 (“Effective Date”) by and between NORD RESOURCES CORPORATION, a Delaware corporation (“Producer”), and IRC NEVADA INC., a Nevada corporation (“IRC”).
AMENDMENT NO. 1 TO ROYALTY PURCHASE AGREEMENTRoyalty Purchase Agreement • March 7th, 2024 • Viracta Therapeutics, Inc. • Pharmaceutical preparations
Contract Type FiledMarch 7th, 2024 Company IndustryThis Amendment No. 1 to Royalty Purchase Agreement (this “Amendment”) is entered into as of March 4, 2024 (the “Amendment Effective Date”) by and between VIRACTA THERAPEUTICS, INC., a corporation organized and existing under the laws of Delaware, with an office located at 2533 South Coast Highway 101, #210, Cardiff CA 92007 (“Viracta”), VIRACTA ROYALTY FUND, LLC, a Delaware limited liability company (collectively, with Viracta, “Seller”), and XOMA (US) LLC, a Delaware limited liability company with its principal place of business at 2200 Powell Street, Suite 310, Emeryville, California 94608 (“Purchaser”). Seller and Purchaser are referred to in this Amendment individually as a “Party” and collectively as the “Parties”. Capitalized terms used herein and not otherwise defined shall have the respective meanings given to such terms in the Royalty Purchase Agreement (defined below).
Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. AMENDMENT NO. 1 TO...Royalty Purchase Agreement • August 8th, 2024 • PTC Therapeutics, Inc. • Pharmaceutical preparations • New York
Contract Type FiledAugust 8th, 2024 Company Industry JurisdictionThis AMENDMENT NO. 1 to the AMENDED AND RESTATED ROYALTY PURCHASE AGREEMENT dated as of October 18, 2023 (the “Purchase Agreement”) and FIRST PUT OPTION EXERCISE AGREEMENT (“Amendment No. 1”), is entered into on this 17th day of June, 2024, by and among PTC Therapeutics, Inc., a Delaware corporation (the “Seller”), Royalty Pharma Investments 2019 ICAV, an Irish collective asset-management vehicle (the “Buyer”) and Royalty Pharma plc, a public limited company established under the laws of England and Wales. Capitalized terms not defined herein have the meanings assigned to them in the Purchase Agreement.
ROYALTY PURCHASE AGREEMENTRoyalty Purchase Agreement • November 13th, 2012 • Arrayit Diagnostics, Inc. • Texas
Contract Type FiledNovember 13th, 2012 Company JurisdictionTHIS AGREEMENT is made and entered into this first day of March, 2012 by and between Recap Marketing and Consulting, LLP, 12000 Westheimer Suite 340, Houston, Texas 77077, (“Seller”) and Arrayit Diagnostics, Inc. Nevada corporation (“Purchaser”).
Via E-mail Thomas BurnsRoyalty Purchase Agreement • February 18th, 2020
Contract Type FiledFebruary 18th, 2020
AMENDING AGREEMENTRoyalty Purchase Agreement • September 22nd, 2021 • mCloud Technologies Corp. • Services-prepackaged software
Contract Type FiledSeptember 22nd, 2021 Company Industry
ROYALTY PURCHASE AGREEMENT QUESTCAP INC.Royalty Purchase Agreement • January 8th, 2020 • Ontario
Contract Type FiledJanuary 8th, 2020 JurisdictionAND WHEREAS the Purchaser has agreed to purchase, and the Vendor has agreed to sell, the Royalty in consideration for the aggregate purchase price of $10,000,000 (the “Purchaser Price”), to be paid by the Purchaser to the Vendor pursuant to and in accordance with the terms of this Agreement;
AMENDMENT NO. 1 TO ROYALTY Purchase AGREEMENTRoyalty Purchase Agreement • August 9th, 2021 • Agenus Inc • Biological products, (no disgnostic substances) • New York
Contract Type FiledAugust 9th, 2021 Company Industry JurisdictionThis Amendment No. 1 to Royalty Purchase Agreement (this “Amendment”) is made and entered into as of June 22, 2021 by and among Antigenics LLC, a Delaware limited liability company (the “Seller”) and the entities set forth on Schedule 1 to the (as defined below) Agreement in the proportions set forth thereon (collectively, the “Buyer”). Capitalized terms used herein but not defined shall have the meanings ascribed to such terms in the Agreement (as defined below).
ROYALTY PURCHASE AGREEMENTRoyalty Purchase Agreement • May 14th, 2021 • Nouveau Monde Graphite Inc.
Contract Type FiledMay 14th, 2021 CompanyThe Owner wishes to grant to the Holder, and the Holder wishes to purchase from the Owner, a 3.0% net smelter royalty in the Property and on all minerals mined, provided or otherwise recovered from the Property (as defined below) subject to and on the terms and conditions set forth herein.
Royalty Purchase Agreement Between REGENXBIO Inc., as Seller the entities set forth on Schedule 1.1 HERETO, as Purchaser, and HCR COLLATERAL MANAGEMENT LLC, as Purchaser Representative Dated as of December 22, 2020Royalty Purchase Agreement • March 1st, 2021 • REGENXBIO Inc. • Biological products, (no disgnostic substances) • New York
Contract Type FiledMarch 1st, 2021 Company Industry JurisdictionRoyalty Purchase Agreement, dated as of December 22, 2020 (this “Agreement”), between REGENXBIO Inc., a Delaware corporation, as Seller (“Seller”), the entities set forth on Schedule 1.1, as Purchaser (collectively, “Purchaser”), and, solely in its capacity as representative of the Purchaser, HCR COLLATERAL MANAGEMENT LLC, a Delaware limited liability company (“HCR Agent”).
Royalty PURCHASE Agreement (Lapon Canyon Royalty; Mineral County, Nevada)Royalty Purchase Agreement • May 29th, 2024 • Nevada Canyon Gold Corp. • Gold and silver ores • Nevada
Contract Type FiledMay 29th, 2024 Company Industry Jurisdiction
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND IS THE TYPE THAT ANAPTYSBIO, INC. TREATS AS PRIVATE OR CONFIDENTIAL. AGREEMENT AND AMENDMENT NO. 1 TO THE ROYALTY PURCHASE...Royalty Purchase Agreement • August 5th, 2024 • Anaptysbio, Inc • Pharmaceutical preparations • New York
Contract Type FiledAugust 5th, 2024 Company Industry JurisdictionTHIS AGREEMENT AND AMENDMENT NO. 1 (this “Amendment”) TO THE ROYALTY PURCHASE AGREEMENT, dated as of October 25, 2021 (the “Original Purchase Agreement”), is effective as of May 8, 2024 (the “Amendment Effective Date”) and is entered into by and between ANAPTYSBIO, INC., a Delaware corporation, as Seller (“Seller”), and SAGARD HEALTHCARE PARTNERS FUNDING BORROWER SPE 2, LP, a Delaware limited partnership (as assignee of Sagard Healthcare Partners (Delaware) II LP, a Delaware limited partnership, which was, in turn, assignee of Sagard Healthcare Royalty Partners, LP, a Cayman Islands exempted limited partnership), as Purchaser (“Purchaser”). Capitalized terms used in this Amendment and not otherwise defined herein shall have the respective meanings ascribed to them in the Original Purchase Agreement (including as may be as ascribed to them in the License Agreement), except as otherwise set forth in Sections 2, 5 and 6 of this Amendment.